24.34
+0.56(+2.35%)
Currency In USD
| Previous Close | 23.78 |
| Open | 22.85 |
| Day High | 24.62 |
| Day Low | 22.85 |
| 52-Week High | 25.6 |
| 52-Week Low | 13.36 |
| Volume | 167,120 |
| Average Volume | 309,108 |
| Market Cap | 615.78M |
| PE | -32.89 |
| EPS | -0.74 |
| Moving Average 50 Days | 22.53 |
| Moving Average 200 Days | 19.17 |
| Change | 0.56 |
If you invested $1000 in LB Pharmaceuticals Inc Common Stock (LBRX) since IPO date, it would be worth $1,406.94 as of March 10, 2026 at a share price of $24.34. Whereas If you bought $1000 worth of LB Pharmaceuticals Inc Common Stock (LBRX) shares 6 months ago, it would be worth $1,406.94 as of March 10, 2026 at a share price of $24.34.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug developmentNEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company de
LB Pharmaceuticals to Participate in Upcoming March Investor Events
GlobeNewswire Inc.
Mar 04, 2026 9:05 PM GMT
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatmen
LB Pharmaceuticals Announces $100.0 Million Private Placement
GlobeNewswire Inc.
Feb 05, 2026 1:00 PM GMT
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsych